Graminex L.L.C. Receives NNHPD Health Canada Approval for PollenAid® and Prostanex®
Graminex® LLC, producer of Graminex® Flower Pollen Extracts™, receives Health Canada Approval under the Natural and Non-prescription Health Products Directorate (NNHPD) for its PollenAid® and Prostanex® Flower Pollen Extract™ formulations.
Health Canada’s certification guarantees that Graminex Products meet the highest quality standards according to the guidelines of Health Canada’s Health Products and Food Branch’s Mandate. The mandated guidelines take an integrated approach to managing the risks and benefits in regards to supplements and health food to safe guard the consumer against inferior products.
“Graminex® now has products that are pre-approved by Health Canada’s NNHPD. We are excited to offer Canadian customers new healthcare products backed by the current certification. Our customers are once again assured that Graminex® continues to meet the highest standards in the market today,” stated Justin E. Ritter, Regulatory Affairs.
“Graminex is pleased to be able to support our Canadian Customers with certified products, in one of the largest supplement markets that generates annual sales surpassing $1.4 billion,” added Heather J. May, COO.
PollenAid® and Prostanex® may help to support men’s prostate health, urinary health, quality of life, and sexual health. Additional claims may be reviewed upon request of the NPN licenses of both products.
About Graminex ® LLC
Graminex® LLC is the leading producer of natural and solvent free Graminex® Flower Pollen Extract™. Graminex® directly owns and manages more than 8,500 acres of farmland in Northwest Ohio to meet its customer’s needs. Graminex’s® active ingredients are grown and processed for the dietary supplement, nutraceutical, pharmaceutical, food and skin care industries. Graminex® markets its own line of dietary supplements, focusing on prostate care, urinary care, menopausal support, and skin care. Partnered with its distributors, retailers and manufacturers, Graminex® products are sold in more than 44 countries on six continents.
For further information please contact Graminex® LLC Public Relations, Colleen May at (419) 278-1023 or by e-mail at info@graminex.com. You may also visit www.graminex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005390/en/
Contact information
Graminex® LLC
Colleen E. May
Public Relations
2-300
County Road C
Deshler, Ohio 43516
(419) 278-1023
or
Justin
E. Ritter
Regulatory Affairs
2-300 County Road C
Deshler,
Ohio 43516
(419) 278-1023
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Decent Cybersecurity to Showcase Post-Quantum Solutions at DSEI Japan 202516.5.2025 10:49:00 EEST | Press release
Decent Cybersecurity announces its participation at DSEI Japan 2025 as the only Slovak cybersecurity company exhibiting at this premier defense event in Makuhari Messe, Chiba (May 21-23, 2025). The company will showcase its advanced post-quantum security solutions for aerospace, defense, and space sectors, including SpaceShield STM, DroneCrypt UTM, and QuantumProof Protocol. "The Indo-Pacific region represents a critical frontier for post-quantum cybersecurity innovation as quantum computing advances threaten traditional encryption," said Matej Michalko, Founder, Chairman and CEO of Decent Cybersecurity. "Our participation demonstrates our commitment to offering Japanese defense and space agencies access to European-certified, quantum-resistant security solutions that protect critical infrastructure against emerging threats." As a holder of NATO, EU, and national security clearances at the "Secret" level, Decent Cybersecurity brings unique post-quantum security credentials to the Japan
LTIMindtree, Eurobank and Fairfax Digital Services Collaborate to Build Digital Innovation Hub in Cyprus16.5.2025 10:00:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the opening of its Digital Innovation Hub at the Research and Innovation Hub of CYENS Center of Excellence. The LTIMindtree Digital Innovation Hub will enable ideation, co-creation and implementation of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers and aligns with the strategic vision of the Cyprus Government to strengthen Cyprus’ role as a regional tech and innovation hub, triggering unique cross-border opportunities for tech collaborations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515054331/en/ Srini Rao EVP & Chief Business Officer- Europe, LTIMindtree | Mr. Nikodemos Damianou, Deputy Minister of Research and Innovation, Govt of Cyprus | Mr. Fokion Karavias, Group CEO, EUROBANK Group | Mr. Sanjay Tugnait, President & CEO, Fairfax Digital along with other esteemed client execu
ROYC Acts as the Structuring and Financial Technology Partner for Riverside for European Wealth Access Fund16.5.2025 09:30:00 EEST | Press release
ROYC, the leading provider of complete private markets operating systems, announces the structuring of a new access fund for Private Wealth launched in collaboration with The Riverside Company. The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 1,000 investments and today has over $12 billion in assets under management. The firm's international private equity and structured capital portfolios include more than 140 companies. The Riverside’s proven investment strategy of acquiring and developing high-potential European SMEs in resilient, growth-oriented sectors, including technology and software, healthcare, advanced manufacturing and consumer products. “This fund represents a unique opportunity for wealth investors to access value creation generally reserved for institutional investors,” says Karsten Langer, Managing Partner at Riverside Europe and contin
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 23:51:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz ® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 21:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508024371/en/ Zynyz logo "The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation," said Hervé Hoppenot,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom